Neuromuscular blockade in an intubated patient is reserved for situations where deep sedation alone cannot achieve safe, effective ventilation or protect the brain. The most common indication is severe ARDS with a PaO2/FiO2 ratio below 120 mmHg, but paralysis also plays a role in managing dangerous ventilator dyssynchrony, elevated intracranial pressure, and refractory shivering during targeted temperature management. In every case, it’s considered a last-line tool, not a default setting.
Severe ARDS and Refractory Hypoxemia
The strongest evidence for paralysis centers on acute respiratory distress syndrome. When a patient’s oxygenation remains dangerously poor despite optimized ventilator settings and deep sedation, typically reflected by a PaO2/FiO2 ratio below 120 mmHg, neuromuscular blockade can improve oxygen levels and reduce the risk of lung injury. Paralysis works here by eliminating any patient effort that fights the ventilator, which allows the lungs to be ventilated with precisely controlled, low-volume breaths that limit further damage.
A systematic review in the Journal of Intensive Care found that blocking agents improved oxygenation after 48 hours in moderate to severe ARDS and lowered the risk of barotrauma (air leaking from the lung) without increasing ICU-acquired weakness. The European Society of Intensive Care Medicine guidelines, however, recommend against routine continuous infusions of paralytics for all patients with moderate-to-severe ARDS. The key distinction is “routine” versus “rescue.” Paralysis is appropriate when a specific patient continues to desaturate or develops complications like pneumothorax despite best-practice ventilation, not as a blanket protocol for every ARDS case.
Ventilator Dyssynchrony That Sedation Cannot Fix
When a patient’s breathing efforts clash with the ventilator, the result is dyssynchrony, and some forms are more dangerous than others. Double triggering occurs when a patient’s inspiratory effort is strong enough to trigger a second mechanical breath before the first one fully deflates, effectively doubling the tidal volume delivered to already-injured lungs. Reverse triggering is a subtler problem seen in deeply sedated patients: the ventilator’s breath itself stimulates the diaphragm to contract, creating a chaotic, stacked breathing pattern.
Both of these patterns can worsen lung injury by delivering unpredictable, oversized breaths. When adjusting ventilator settings and deepening sedation fail to resolve dangerous dyssynchrony, chemical paralysis eliminates the patient’s muscle activity entirely and restores full ventilator control. This is particularly relevant in patients with ARDS, where even small increases in tidal volume can cause harm.
Elevated Intracranial Pressure
In patients with traumatic brain injury, stroke, or other causes of raised intracranial pressure, any sudden spike in pressure inside the skull can cause devastating secondary damage. Coughing, straining against the endotracheal tube, or fighting the ventilator all sharply raise intracranial pressure. Deep sedation and pain control are the first-line approach because they reduce coughing and agitation while still allowing some neurological assessment.
Paralysis is used rarely in this setting, reserved for cases where intracranial pressure remains critically elevated despite maximum sedation. The trade-off is significant: once a patient is paralyzed, the clinical neurological exam (pupil reactivity aside) becomes impossible, so teams lose a key monitoring tool. For that reason, it’s typically a short-term bridge while other interventions, such as surgical drainage, are arranged.
Shivering During Targeted Temperature Management
After cardiac arrest, targeted temperature management (therapeutic cooling) improves neurological outcomes, but the body fights cooling by shivering. Shivering generates heat, raises metabolic demand, and can completely undermine the cooling protocol. Treatment follows a stepwise approach: surface warming of the hands and face, then oral or IV medications that suppress the shiver response.
Neuromuscular blockade is the last step in this escalation. Most protocols reserve it for severe shivering that persists after all other pharmacologic interventions have failed, assessed using a bedside shivering scale. The goal is to provide effective shivering suppression with the least amount of paralysis necessary, because continuous blockade in this population complicates the neurological assessment that determines prognosis.
Sedation Depth Before Starting Paralysis
This is one of the most critical safety requirements. Paralytics eliminate all voluntary movement but have zero effect on consciousness or pain perception. A patient who is inadequately sedated but fully paralyzed is awake, aware, and unable to signal distress. This is a preventable catastrophe.
Before initiating neuromuscular blockade, sedation must be deepened to a Richmond Agitation-Sedation Scale (RASS) score of negative 4 to negative 5, meaning the patient is deeply sedated or unarousable. This is a departure from the lighter sedation targets (RASS 0 to negative 1) used for most ventilated patients. Brain-function monitors that use processed EEG, targeting a score of 40 to 60, provide an additional layer of reassurance that the patient is not aware once paralysis removes behavioral cues. Sedation should always be established and verified before the first dose of a paralytic agent, and it must be continuously maintained for the entire duration of blockade.
Choosing the Right Agent
Two paralytics dominate ICU practice, and the choice between them depends largely on organ function. Cisatracurium breaks down spontaneously in the bloodstream through a chemical process called Hofmann elimination, meaning it does not depend on the liver or kidneys to clear it. This makes it the preferred agent for patients with organ failure, and it’s typically given as a continuous drip for sustained, predictable paralysis.
Rocuronium has a faster onset and is commonly given as intermittent bolus doses, which allows for periodic reassessment between doses. It does rely on liver metabolism for clearance, so its effects can become prolonged and unpredictable in patients with hepatic dysfunction. In a patient with normal organ function who needs short-duration paralysis, rocuronium’s flexibility is an advantage. In a patient with multi-organ failure who needs sustained blockade, cisatracurium is generally the safer choice.
Monitoring Paralysis Depth
Once a patient is on continuous paralysis, the depth of blockade needs regular assessment using a peripheral nerve stimulator. This device delivers a series of four small electrical impulses to a nerve (usually at the wrist) and counts how many muscle twitches result, called a train-of-four (TOF) measurement. Four twitches means minimal blockade; zero means complete paralysis.
Practice varies, but most ICU protocols titrate the paralytic dose to achieve one or two twitches out of four, checked every four hours. Some evidence suggests that dosing to just beyond four visible twitches (roughly 50% blockade) is sufficient to prevent meaningful patient effort, including the ability to lift the head, in about 70% of patients. The goal is using the minimum effective dose: enough to achieve the clinical objective, whether that’s ventilator synchrony or ICP control, without unnecessarily deep paralysis that increases the risk of complications.
Risks of Prolonged Paralysis
The most feared complication is ICU-acquired weakness, a debilitating condition where patients emerge from critical illness unable to move their limbs or breathe independently. A meta-analysis of 30 studies enrolling nearly 3,840 patients found that paralytic use increased the odds of developing ICU-acquired weakness by roughly 2.8 times. The quality of evidence was low, and the researchers noted that untangling the contribution of paralytics from other risk factors (sepsis, steroids, prolonged immobility, critical illness itself) remains difficult.
Still, the signal is strong enough to reinforce a core principle: use paralysis for the shortest duration possible. Most protocols aim for 48 hours or less, with daily reassessment of whether the indication still exists. Stopping the infusion each morning to evaluate whether the patient still needs blockade is a common strategy to limit exposure.
Caring for a Paralyzed Patient
Paralysis creates vulnerabilities that require specific nursing attention. The most overlooked is eye care. Paralyzed patients cannot blink, and incomplete eyelid closure exposes the cornea to drying, abrasion, and potentially ulceration or infection. Applying lubricating ointment to both eyes every four to six hours significantly reduces the incidence of corneal damage compared to simply taping the eyelids shut. Moisture chambers and polyethylene covers offer similar protection to ointment, but lubricating drops alone are not enough.
Beyond eye care, paralyzed patients need aggressive repositioning to prevent pressure injuries, since they cannot shift their weight. Venous thromboembolism prevention becomes even more important without any muscle activity in the legs. And because the patient cannot cough, airway suctioning must be performed on a regular schedule guided by secretion assessment rather than waiting for the patient to signal distress.